Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors

Thomas J. Fraites, Mary R. Schleissing, R. Andrew Shanely, Glenn A. Walter, Denise A. Cloutier, Irene Zolotukhin, Daniel F. Pauly, Nina Raben, Paul H. Plotz, Scott K. Powers, Paul D. Kessler, Barry J. Byrne

Research output: Contribution to journalArticle

Abstract

Pompe disease is a lysosomal storage disease caused by the absence of acid α-1,4 glucosidase (GAA). The pathophysiology of Pompe disease includes generalized myopathy of both cardiac and skeletal muscle. We sought to use recombinant adeno-associated virus (rAAV) vectors to deliver functional GAA genes in vitro and in vivo. Myotubes and fibroblasts from Pompe patients were transduced in vitro with rAAV2-GAA. At 14 days postinfection, GAA activities were at least fourfold higher than in their respective untransduced controls, with a 10-fold increase observed in GAA-deficient myotubes. BALB/c and Gaa-/- mice were also treated with rAAV vectors. Persistent expression of vector-derived human GAA was observed in BALB/c mice up to 6 months after treatment. In Gaa-/- mice, intramuscular and intramyocardial delivery of rAAV2-Gaa (carrying the mouse Gaa cDNA) resulted in near-normal enzyme activities. Skeletal muscle contractility was partially restored in the soleus muscles of treated Gaa-/- mice, indicating the potential for vector-mediated restoration of both enzymatic activity and muscle function. Furthermore, intramuscular treatment with a recombinant AAV serotype 1 vector (rAAV1-Gaa) led to nearly eight times normal enzymatic activity in Gaa-/- mice, with concomitant glycogen clearance as assessed in vitro and by proton magnetic resonance spectroscopy.

Original languageEnglish (US)
Pages (from-to)571-578
Number of pages8
JournalMolecular Therapy
Volume5
Issue number5 I
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Glycogen Storage Disease Type II
Dependovirus
Skeletal Muscle
Skeletal Muscle Fibers
Glucosidases
Lysosomal Storage Diseases
Muscular Diseases
Glycogen
Myocardium
Complementary DNA
Fibroblasts
Muscles
Acids
Enzymes
Therapeutics
Genes
In Vitro Techniques

Keywords

  • Cardiovascular diseases
  • Gene therapy
  • Glycogen storage disease type II
  • Lysosomal storage diseases
  • Musculoskeletal diseases

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Fraites, T. J., Schleissing, M. R., Shanely, R. A., Walter, G. A., Cloutier, D. A., Zolotukhin, I., ... Byrne, B. J. (2002). Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors. Molecular Therapy, 5(5 I), 571-578. https://doi.org/10.1006/mthe.2002.0580

Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors. / Fraites, Thomas J.; Schleissing, Mary R.; Shanely, R. Andrew; Walter, Glenn A.; Cloutier, Denise A.; Zolotukhin, Irene; Pauly, Daniel F.; Raben, Nina; Plotz, Paul H.; Powers, Scott K.; Kessler, Paul D.; Byrne, Barry J.

In: Molecular Therapy, Vol. 5, No. 5 I, 2002, p. 571-578.

Research output: Contribution to journalArticle

Fraites, TJ, Schleissing, MR, Shanely, RA, Walter, GA, Cloutier, DA, Zolotukhin, I, Pauly, DF, Raben, N, Plotz, PH, Powers, SK, Kessler, PD & Byrne, BJ 2002, 'Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors', Molecular Therapy, vol. 5, no. 5 I, pp. 571-578. https://doi.org/10.1006/mthe.2002.0580
Fraites, Thomas J. ; Schleissing, Mary R. ; Shanely, R. Andrew ; Walter, Glenn A. ; Cloutier, Denise A. ; Zolotukhin, Irene ; Pauly, Daniel F. ; Raben, Nina ; Plotz, Paul H. ; Powers, Scott K. ; Kessler, Paul D. ; Byrne, Barry J. / Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors. In: Molecular Therapy. 2002 ; Vol. 5, No. 5 I. pp. 571-578.
@article{541479169e074260be6aa7d87e5c9c14,
title = "Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors",
abstract = "Pompe disease is a lysosomal storage disease caused by the absence of acid α-1,4 glucosidase (GAA). The pathophysiology of Pompe disease includes generalized myopathy of both cardiac and skeletal muscle. We sought to use recombinant adeno-associated virus (rAAV) vectors to deliver functional GAA genes in vitro and in vivo. Myotubes and fibroblasts from Pompe patients were transduced in vitro with rAAV2-GAA. At 14 days postinfection, GAA activities were at least fourfold higher than in their respective untransduced controls, with a 10-fold increase observed in GAA-deficient myotubes. BALB/c and Gaa-/- mice were also treated with rAAV vectors. Persistent expression of vector-derived human GAA was observed in BALB/c mice up to 6 months after treatment. In Gaa-/- mice, intramuscular and intramyocardial delivery of rAAV2-Gaa (carrying the mouse Gaa cDNA) resulted in near-normal enzyme activities. Skeletal muscle contractility was partially restored in the soleus muscles of treated Gaa-/- mice, indicating the potential for vector-mediated restoration of both enzymatic activity and muscle function. Furthermore, intramuscular treatment with a recombinant AAV serotype 1 vector (rAAV1-Gaa) led to nearly eight times normal enzymatic activity in Gaa-/- mice, with concomitant glycogen clearance as assessed in vitro and by proton magnetic resonance spectroscopy.",
keywords = "Cardiovascular diseases, Gene therapy, Glycogen storage disease type II, Lysosomal storage diseases, Musculoskeletal diseases",
author = "Fraites, {Thomas J.} and Schleissing, {Mary R.} and Shanely, {R. Andrew} and Walter, {Glenn A.} and Cloutier, {Denise A.} and Irene Zolotukhin and Pauly, {Daniel F.} and Nina Raben and Plotz, {Paul H.} and Powers, {Scott K.} and Kessler, {Paul D.} and Byrne, {Barry J.}",
year = "2002",
doi = "10.1006/mthe.2002.0580",
language = "English (US)",
volume = "5",
pages = "571--578",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5 I",

}

TY - JOUR

T1 - Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors

AU - Fraites, Thomas J.

AU - Schleissing, Mary R.

AU - Shanely, R. Andrew

AU - Walter, Glenn A.

AU - Cloutier, Denise A.

AU - Zolotukhin, Irene

AU - Pauly, Daniel F.

AU - Raben, Nina

AU - Plotz, Paul H.

AU - Powers, Scott K.

AU - Kessler, Paul D.

AU - Byrne, Barry J.

PY - 2002

Y1 - 2002

N2 - Pompe disease is a lysosomal storage disease caused by the absence of acid α-1,4 glucosidase (GAA). The pathophysiology of Pompe disease includes generalized myopathy of both cardiac and skeletal muscle. We sought to use recombinant adeno-associated virus (rAAV) vectors to deliver functional GAA genes in vitro and in vivo. Myotubes and fibroblasts from Pompe patients were transduced in vitro with rAAV2-GAA. At 14 days postinfection, GAA activities were at least fourfold higher than in their respective untransduced controls, with a 10-fold increase observed in GAA-deficient myotubes. BALB/c and Gaa-/- mice were also treated with rAAV vectors. Persistent expression of vector-derived human GAA was observed in BALB/c mice up to 6 months after treatment. In Gaa-/- mice, intramuscular and intramyocardial delivery of rAAV2-Gaa (carrying the mouse Gaa cDNA) resulted in near-normal enzyme activities. Skeletal muscle contractility was partially restored in the soleus muscles of treated Gaa-/- mice, indicating the potential for vector-mediated restoration of both enzymatic activity and muscle function. Furthermore, intramuscular treatment with a recombinant AAV serotype 1 vector (rAAV1-Gaa) led to nearly eight times normal enzymatic activity in Gaa-/- mice, with concomitant glycogen clearance as assessed in vitro and by proton magnetic resonance spectroscopy.

AB - Pompe disease is a lysosomal storage disease caused by the absence of acid α-1,4 glucosidase (GAA). The pathophysiology of Pompe disease includes generalized myopathy of both cardiac and skeletal muscle. We sought to use recombinant adeno-associated virus (rAAV) vectors to deliver functional GAA genes in vitro and in vivo. Myotubes and fibroblasts from Pompe patients were transduced in vitro with rAAV2-GAA. At 14 days postinfection, GAA activities were at least fourfold higher than in their respective untransduced controls, with a 10-fold increase observed in GAA-deficient myotubes. BALB/c and Gaa-/- mice were also treated with rAAV vectors. Persistent expression of vector-derived human GAA was observed in BALB/c mice up to 6 months after treatment. In Gaa-/- mice, intramuscular and intramyocardial delivery of rAAV2-Gaa (carrying the mouse Gaa cDNA) resulted in near-normal enzyme activities. Skeletal muscle contractility was partially restored in the soleus muscles of treated Gaa-/- mice, indicating the potential for vector-mediated restoration of both enzymatic activity and muscle function. Furthermore, intramuscular treatment with a recombinant AAV serotype 1 vector (rAAV1-Gaa) led to nearly eight times normal enzymatic activity in Gaa-/- mice, with concomitant glycogen clearance as assessed in vitro and by proton magnetic resonance spectroscopy.

KW - Cardiovascular diseases

KW - Gene therapy

KW - Glycogen storage disease type II

KW - Lysosomal storage diseases

KW - Musculoskeletal diseases

UR - http://www.scopus.com/inward/record.url?scp=0036099319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036099319&partnerID=8YFLogxK

U2 - 10.1006/mthe.2002.0580

DO - 10.1006/mthe.2002.0580

M3 - Article

C2 - 11991748

AN - SCOPUS:0036099319

VL - 5

SP - 571

EP - 578

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5 I

ER -